Australian cancer biotech raising $20m after delaying Nasdaq float

According to The Australian Financial Review, Sydney-based biotech EnGeneIC is tapping investors to raise $20 million in bridging funding to buy time until the IPO market reopens and the company can undertake a Nasdaq listing next year.
The company, which was founded in 2001 by former CSIRO scientists Jennifer MacDiarmid and Himanshu Brahmbhatt, who still serve as co-CEOs, has created a new way of delivering cancer drugs that is more potent and less toxic than existing treatments.

https://www.afr.com/companies/healthcare-and-fitness/cancer-biotech-raising-20m-after-delaying-nasdaq-float-20221111-p5bxgo